2014 - 2015年纽约市使用衣原体感染快速性伴治疗法时处方对性伴治疗的影响

The Impact of Prescriptions on Sex Partner Treatment Using Expedited Partner Therapy for Chlamydia trachomatis Infection, New York City, 2014-2015.

作者信息

Oliver Ashley, Rogers Meighan, Schillinger Julia A

机构信息

From the *Department of Epidemiology, Columbia University Mailman School of Public Health; †Bureau of STD Prevention and Control, New York City Department of Health and Mental Hygiene, New York, New York; and ‡Division of STD Prevention, National Center for HIV, Hepatitis, TB, and STD Prevention, Atlanta, GA.

出版信息

Sex Transm Dis. 2016 Nov;43(11):673-678. doi: 10.1097/OLQ.0000000000000511.

DOI:10.1097/OLQ.0000000000000511

PMID:27893595

Abstract

BACKGROUND

Chlamydia trachomatis reinfections, often resulting from resuming sex with untreated partners, can increase the risk of pelvic inflammatory disease, infertility, and ectopic pregnancy. Expedited partner therapy (EPT) has been shown to prevent reinfection when provided as medication (Medication-EPT) that patients give to sex partners; however, EPT is often provided as a prescription (Prescription-EPT). We compared partner treatment outcomes for Medication-EPT versus Prescription-EPT.

METHODS

We conducted telephone interviews from October 2014 to October 2015 with a population-based random sample of women aged 15 to 25 years diagnosed with Chlamydia trachomatis. Interview questions included: demographics, patient-treatment, EPT type, and patient report of partner treatment. The main outcomes explored were: proportion of women receiving EPT, proportion of Prescription-EPT and Medication-EPT, and proportion of partners reported as treated. We used χ and Fisher exact tests for analysis.

RESULTS

A total of 421 women completed the interview; 357 (84.8%) of 421 women reported having been treated, and 109/357 (30.5%) received EPT for any partner. Women given a prescription (vs medication) for their own treatment were more likely to receive EPT (odds ratio, 1.57; P = 0.05) and to receive Prescription-EPT specifically (odds ratio, 6.85; P < 0.0001). Forty-eight (52.2%) of 92 patients who received EPT for their most recent partner received Prescription-EPT. There was no difference by EPT type in proportion of index patients reporting partner treatment: 77.1% (37/48) for Prescription-EPT versus 79.5% (35/44) for Medication-EPT (P > 0.05).

CONCLUSIONS

Prescription-EPT and Medication-EPT appear to result in comparable rates of partner treatment. Further research is needed to assess the effects of Prescription-EPT on partner treatment among adolescents and in other contexts.

摘要

背景

沙眼衣原体再感染通常是由于与未治疗的性伴侣恢复性行为所致，可增加盆腔炎、不孕和异位妊娠的风险。当作为患者给予性伴侣的药物（药物加速性伴侣治疗）提供时，加速性伴侣治疗（EPT）已被证明可预防再感染；然而，EPT通常作为处方（处方加速性伴侣治疗）提供。我们比较了药物加速性伴侣治疗与处方加速性伴侣治疗的性伴侣治疗结果。

方法

2014年10月至2015年10月，我们对15至25岁被诊断为沙眼衣原体感染的女性进行了基于人群的随机抽样电话访谈。访谈问题包括：人口统计学、患者治疗情况、EPT类型以及患者对性伴侣治疗的报告。探讨的主要结果包括：接受EPT的女性比例、处方加速性伴侣治疗和药物加速性伴侣治疗的比例以及报告接受治疗的性伴侣比例。我们使用χ检验和Fisher精确检验进行分析。

结果

共有421名女性完成了访谈；421名女性中有357名（84.8%）报告已接受治疗，其中109/357名（30.5%）为任何性伴侣接受了EPT。接受自己治疗处方（而非药物）的女性更有可能接受EPT（优势比，1.57；P = 0.05），尤其更有可能接受处方加速性伴侣治疗（优势比，6.85；P < 0.0001）。92名最近为其性伴侣接受EPT的患者中有48名（52.2%）接受了处方加速性伴侣治疗。在报告性伴侣治疗情况的索引患者比例方面，EPT类型之间没有差异：处方加速性伴侣治疗为77.1%（37/48），药物加速性伴侣治疗为79.5%（35/44）（P > 0.05）。